Online News Kits

Archives: Search this section

 
Asset Types              
 
 
Transcatheter Cardiovascular Therapeutics (TCT) Meeting 2015

Boston Scientific (NYSE: BSX) today announced key data presentations spanning its broad interventional cardiology, structural heart and peripheral interventions portfolios to be shared at the 27th...

Boston Scientific Announces Additional Investment And Right To Acquire MValve Technologies
(Release)
MARLBOROUGH, Mass. and HERZLIYA, Israel, Oct. 8, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has closed on an additional round of financing with MValve...
Boston Scientific Announces Scheduled Presentations At TCT 2015
(Release)
MARLBOROUGH, Mass., Oct. 7, 2015 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced key data presentations spanning its broad interventional cardiology, structural heart and peripheral...
Boston Scientific Receives FDA Approval For SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System
(Release)
MARLBOROUGH, Mass., Oct. 5, 2015 /PRNewswire/ -- Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting...
Eluvia™ Drug-eluting Vascular Stent System Demonstrates 12-month Primary Patency Of 96.1 Percent
(Release)
MARLBOROUGH, Mass., Sept. 28, 2015 /PRNewswire/ -- New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific (NYSE: BSX) Eluvia™ Drug-Eluting Vascular...
About Our Global Headquarters, Marlborough MA

Boston Scientific Corporation recently established its new global headquarters in Marlborough, MA, on a state-of-the-art campus designed to drive global connectivity, collaboration and technology...

Eluvia™ Drug-Eluting Vascular Stent System
(Photo)
The Eluvia Drug-Eluting Stent System is designed to restore blood flow in arteries above the knee, specifically the superficial femoral artery and proximal popliteal artery. The Eluvia Stent System has CE Mark approval. In the U.S., the Eluvia Stent System is an investigational device and not available for sale.
THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY PUBLISHES BRONCHIAL THERMOPLASTY DATA DEMONSTRATING SUSTAINED REDUCTION IN SEVERE ASTHMA ATTACKS OVER FIVE YEARS
(Release)
Natick, Mass. (September 4, 2013) /PRNewswire/ — A breakthrough Boston Scientific technology for the treatment of severe asthma has been shown to be safe and effective over at least five years,...